Spots Global Cancer Trial Database for laromustine
Every month we try and update this database with for laromustine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer | NCT00282022 | Lung Cancer | laromustine | 18 Years - | National Cancer Institute (NCI) | |
| VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer | NCT00282022 | Lung Cancer | laromustine | 18 Years - | National Cancer Institute (NCI) | |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | NCT00070538 | Leukemia Myelodysplastic... | cytarabine laromustine | 18 Years - | National Cancer Institute (NCI) | |
| VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia | NCT00354276 | Leukemia | cytarabine laromustine | 60 Years - | National Cancer Institute (NCI) | |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | NCT00070538 | Leukemia Myelodysplastic... | cytarabine laromustine | 18 Years - | National Cancer Institute (NCI) | |
| VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors | NCT00098761 | Brain and Centr... | laromustine | - 21 Years | Pediatric Brain Tumor Consortium | |
| Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias | NCT00098436 | Leukemia | laromustine temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors | NCT00098761 | Brain and Centr... | laromustine | - 21 Years | Pediatric Brain Tumor Consortium | |
| Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias | NCT00098436 | Leukemia | laromustine temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia | NCT00112554 | Leukemia | cytarabine laromustine placebo | 18 Years - | National Cancer Institute (NCI) | |
| VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders | NCT00304005 | Leukemia Lymphoma | laromustine | 18 Years - | National Cancer Institute (NCI) | |
| VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer | NCT00282022 | Lung Cancer | laromustine | 18 Years - | National Cancer Institute (NCI) | |
| Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia | NCT00112554 | Leukemia | cytarabine laromustine placebo | 18 Years - | National Cancer Institute (NCI) | |
| VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders | NCT00304005 | Leukemia Lymphoma | laromustine | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
